This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Inherited thrombophilia and pregnancy complications revisited.
Obstetrics and gynecology · 2008
Latest funding
- $20,000
PECAN - Pulmonary Embolism Canada
CIHR · 2024 · Co-investigator
- $634,951
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
CIHR · 2023 · Co-investigator
- $374,850
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial
CIHR · 2023 · Principal investigator
1 publications.
Inherited thrombophilia and pregnancy complications revisited.
Rodger MA, Paidas M, McLintock C, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I
PECAN - Pulmonary Embolism Canada
Principal investigators: Castellucci, Lana; de Wit, Kerstin; Mendelson, Asher A
Keywords: Pulmonary Embolism
COBRRA trial: Comparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
Principal investigators: Castellucci, Lana
Keywords: Anticoagulation; Bleeding Risk; Venous Thromboembolism
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial
Principal investigators: Carrier, Marc; Kahn, Susan R; Le Gal, Grégoire; Shivakumar, Sudeep P; Siegal, Deborah M
Keywords: Clotting Defects/Thrombosis; Colchicine; Deep Vein Thrombosis; Inflammation; Pilot Study; Post Thrombotic Syndrome; Randomized Controlled Trial; Venous Thromboembolism
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
Principal investigators: Castellucci, Lana; de Wit, Kerstin; Le Gal, Grégoire; Parkash, Ratika
Keywords: Atrial Fibrillation, Bleeding, Anticoagulation
Comparison of Bleeding Risk between Rivaroxaban and Apixaban in Atrial Fibrillation (COBRRA AF)
Principal investigators: Castellucci, Lana; de Wit, Kerstin; Le Gal, Grégoire; Perry, Jeffrey J
Keywords: Atrial Fibrillation, Bleeding, Anticoagulation
StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)
Principal investigators: Delluc, Aurelien; Rodger, Marc A
Keywords: Adjuvent; Arterial Vascular Events; Deep Vein Thrombosis; Post-Thrombotic Syndrome; Pulmonary Embolism; Randomized Controlled Trial; Rosuvastatin; Secondary Prevention; Statin; Venous Thromboembolism
Safely Ruling out Deep Vein Thrombosis in Pregnancy with the LEFt Clinical Decision Rule and and D-dimer (the LEaD study): A Prospective Cohort Study
Principal investigators: Rodger, Marc A
Keywords: Clinical Decision Rule; D-Dimer; Deep Vein Thrombosis; Diagnosis; Pregnancy
Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial
Principal investigators: Castellucci, Lana; Rodger, Marc A
Keywords: Anticoagulation; Bleeding Risk; Venous Thromboembolism
Statins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Pilot Randomized Trial)
Principal investigators: Rodger, Marc A
Keywords: Arterial Vascular Events; Pilot Trial; Post Thrombotic Syndrome; Randomized Controlled Trial; Rosuvastatin; Statin; Treatment; Venous Thromboembolism
Development of a patient outcomes driven research priority through effective patient engagement within Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (VECTOR) Network
Principal investigators: Duffett, Lisa
Keywords: Patient Engagement; Patient Oriented Research; Venous Thromboembolic Disease
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.